FDA’s Jenkins Revives Intermediate Drug Class Talk In Plan B’s Wake
By
Malcolm Spicer, Sue Sutter / Email the Authors / “The Tan Sheet” Dec. 12, 2011, Vol. 19, No. 50
Rx-to-OTC Switch / Word Count: 811 / Article # 05111212014
Executive Summary
FDA new drugs chief John Jenkins says the Plan B decision and failed statin switch attempts should prompt a discussion of alternative pathways to drug access. The current prescription/nonprescription system “maybe … doesn’t work very well’ for some drugs, he says.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.